The United States: Global Leadership in the Development of Rare Disease Treatments

In an era of healthcare reform and heightened scrutiny of pharmaceutical innovation, America’s leadership in rare disease drug development stands out as a remarkable achievement. This progress has been shaped by the dedication of the rare disease patient community—families and advocacy organizations like the National Organization for Rare Disorders (NORD), the Friedreich’s Ataxia Research Alliance […]
